000058376 001__ 58376
000058376 005__ 20170504094950.0
000058376 0247_ $$2doi$$a10.1007/s40268-013-0011-y
000058376 0248_ $$2sideral$$a81694
000058376 037__ $$aART-2013-81694
000058376 041__ $$aeng
000058376 100__ $$aBaron, J.A.
000058376 245__ $$aGastrointestinal adverse effects of short-term aspirin use: A meta-analysis of published randomized controlled trials
000058376 260__ $$c2013
000058376 5060_ $$aAccess copy available to the general public$$fUnrestricted
000058376 5203_ $$aBackground and Objectives: Aspirin is widely used for short-term treatment of pain, fever or colds, but there are only limited data regarding the safety of this use. To summarize the available data on this topic, we conducted a meta-analysis of the published clinical trial literature regarding the gastrointestinal adverse effects of short-term use of aspirin in comparison with placebo and other medications commonly used for the same purpose.
Data Sources and Methods: An extensive literature search identified 119,310 articles regarding possible adverse effects of aspirin, among which 23,131 appeared to possibly include relevant data. An automated text-mining procedure was used to score the references for potential relevance for the meta-analysis. The 3,983 highest-scoring articles were reviewed individually to identify those with data that could be included in this analysis. Ultimately, 78 relevant articles were identified that contained gastrointestinal adverse event data from clinical trials of aspirin versus placebo or an active comparator. Odds ratios (ORs) computed using a Mantel–Haenszel estimator were used to summarize the comparative effects on dyspepsia, nausea/vomiting, and abdominal pain, considered separately and also aggregated as ‘minor gastrointestinal events’. Gastrointestinal bleeds, ulcers, and perforations were also investigated.
Results: Data were obtained regarding 19,829 subjects (34 % treated with aspirin, 17 % placebo, and 49 % an active comparator). About half of the aspirin subjects took a single dose. Aspirin was associated with a higher risk of minor gastrointestinal events than placebo or active comparators: the summary ORs were 1.46 (95 % confidence interval [CI] 1.15–1.86) and 1.81 (95 % CI 1.61–2.04), respectively. Ulcers, perforation, and serious bleeding were not seen after use of aspirin or any of the other interventions.
Conclusions: During short-term use, aspirin is associated with a higher frequency of gastrointestinal complaints than other medications commonly used for treatment of pain, colds, and fever. Serious adverse events were not observed with aspirin or any of the comparators.
Electronic supplementary material: The online version of this article (doi:10.1007/s40268-013-0011-y) contains supplementary material, which is available to authorized users.
000058376 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000058376 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000058376 700__ $$aSenn, S.
000058376 700__ $$aVoelker, M.
000058376 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, A.$$uUniversidad de Zaragoza
000058376 700__ $$aLaurora, I.
000058376 700__ $$aThielemann, W.
000058376 700__ $$aBrückner, A.
000058376 700__ $$aMcCarthy, D.
000058376 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDepartamento de Medicina, Psiquiatría y Dermatología$$cMedicina
000058376 773__ $$g13, 1 (2013), 9-16$$pDRUGS IN R&D$$tDRUGS IN R&D$$x1174-5886
000058376 8564_ $$s303398$$uhttps://zaguan.unizar.es/record/58376/files/texto_completo.pdf$$yVersión publicada
000058376 8564_ $$s90195$$uhttps://zaguan.unizar.es/record/58376/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000058376 909CO $$ooai:zaguan.unizar.es:58376$$particulos$$pdriver
000058376 951__ $$a2017-05-04-09:46:26
000058376 980__ $$aARTICLE